Skip to main content

Table 5 Genotyping pfmdr1 N86Y and pfk13 SNPs at D0, D1 and day of recurrent parasitaemia

From: Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether–lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tanzania: a randomized controlled trial

 

Baseline control patientsa

Recurrent infections

D0

D0

D1

Day of parasite recurrence

pfmdr1 PCR success rate n/N,  %

45/46, 97.8

35/35, 100

34/35, 97.2

28/35, 80

pfmdr1 N86 prevalence, n/N, % (95% CI)

43/45, 95.6 (84.9–99.5)b

34/35, 97.1 (85–100)

33/34, 97.1 (84.7–100)

28/28, 100 (87.7–100)

pfk13 PCR success rate n/N, %

42/46, 91.3

34/35, 97.1

30/35, 85.7

26/35, 74

Prevalence of SNPs in K13 n/N, % (95% CI)

2/35, 5.9 (0.7–19.7)

2/34, 5.9 (0.7–19.7)

ND

1/26, 3.9 (0.1–19.6)

  1. aBaseline control were D0 samples from 46 randomly selected patients (23 from each arm) without recurrent parasitaemia
  2. bThere was one patient out of 43 with mixed N/Y pfmdr1 genotype